4D Molecular Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 100.84 million compared to USD 107.49 million a year ago. Basic loss per share from continuing operations was USD 2.58 compared to USD 3.32 a year ago.